First AD

Second AD

Understanding the Impact of COSMIC-311 and Sequencing in DTC

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC)

Peer Exchange

Marcia Brose, MD, examines data from the COSMIC-311 study, emphasizing the importance of promptly initiating second-line therapy for patients who have progressed on first-line treatments. 

Understanding the Impact of COSMIC-311 and Sequencing in DTC 

Differentiated Thyroid Cancer: Examining Key Epidemiological Trends 

Exploring Incidence and Histology of Differentiated Thyroid Cancer 

Determining Prognosis for Patients with Differentiated Thyroid Cancer 

Predisposition for Patients Developing DTC: Age and Gender 

The Role of Molecular Diagnostics in Real-World DTC Management 

Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

The Importance of Thyroidectomy in DTC Patient Care 

Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression 

Identifying RAI-Refractory Disease: A Key Aspect of DTC Management 

SELECT Trial & DECISION Trial Outcomes and Lessons Learned 

Determining Which DTC Patients May Benefit from Systemic Therapy

Exploring Real-World Evidence Presented at ATA 2023

Toxicity Profiles for DTC Guidelines Therapies 

Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment

Neoadjuvant Approach in RAI-R-DTC

Phase 2 ATLEP Trial Results 

Reflecting on Differentiated Thyroid Cancer: Final Insights